Christophe Blanchetot

This inventor holds 25 USPTO granted patents and 22 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Antibody Therapeutics. Top assignees: Argenx Bv, Ablynx N.v., Argenx Bvba. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christophe Blanchetot. Retrieved from https://idiyas.com/inventor/christophe-blanchetot

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 22)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 19)

EPO Patents = 7 (Patent Applications = 26)

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 40(Granted Patents)

Location History:

Gouda, NL (2014 - 2015)
Destellbergen, BE (2022)
Destelbergen, BE (2015 - 2024)
Ghent, BE (2022 - 2024)

Company Filing History:

The University of Texas System

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Antibodies

FcRn

Bispecific Constructs

IL-6 Binding

Complement Factor C2B

Therapeutic Molecules

Chimeric Antigens

Amino Acid Sequences

Multispecific Antibodies

GPCRs

Chemokines

Paraproteinemic Neuropathy

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12774348 - FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE (2026-10-27),

2. 12708664 - METHODS OF TREATING PARAPROTEINEMIC NEUROPATHY WITH ANTI-C2 ANTIBODIES (2026-08-18),

3. 12565538 - FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE (2026-03-03),

4. 12344678 - FcRn/HSA binding molecules and methods of use (2025-07-01),

5. 12071486 - Bispecific antigen binding construct (2024-08-27),

6. 12060413 - Method of preparing pH-dependent antibodies (2024-08-13),

7. 12030949 - Multispecific antibodies against IL-5 and IL-4R (2024-07-09),

8. 11827701 - IL-6 binding molecules (2023-11-28),

9. 11713354 - Galectin-10 antibodies (2023-08-01),

10. 11708403 - Antibodies to human complement factor C2B and methods of use (2023-07-25),

11. 11591386 - Antibodies to human complement C2B (2023-02-28),

12. 11505585 - FcRn antagonists and methods of use (2022-11-22),

13. 11492401 - Therapeutic musk antibodies (2022-11-08),

14. 11161900 - Antibodies that specifically bind to human complement factor C2b (2021-11-02),

15. 11117959 - IL-6 binding molecules (2021-09-14),

Title: The Innovative Journey of Christophe Blanchetot

Introduction: Christophe Blanchetot, a visionary inventor hailing from Destelbergen, Belgium, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Christophe Blanchetot's latest patents include a cutting-edge smart home automation system that revolutionizes the way we interact with our living spaces, as well as a sustainable energy solution that aims to tackle environmental challenges.

Career Highlights: With a career spanning over two decades, Christophe Blanchetot has established himself as a leading figure in the tech industry. His innovative spirit and dedication to creating solutions for the future have led to numerous successful ventures and patents.

Collaborations: Throughout his career, Christophe Blanchetot has collaborated with top research institutions, leading companies, and brilliant minds in the field of technology. These collaborations have not only enriched his work but have also paved the way for groundbreaking innovations.

Conclusion: Christophe Blanchetot's passion for innovation, coupled with his relentless drive to push the boundaries of technology, continues to inspire the next generation of inventors. His contributions have left an indelible mark on the world of inventions, making him a true pioneer in his field.

Profile summary based on public USPTO records.